Autolus Therapeutics PLC (NAS:AUTL)
$ 3.92 0.05 (1.29%) Market Cap: 1.04 Bil Enterprise Value: 335.67 Mil PE Ratio: 0 PB Ratio: 1.79 GF Score: 55/100

Autolus Therapeutics PLC to Discuss the ALLCAR19 Data Presented at AACR Conference Call Transcript

Apr 02, 2019 / 12:00PM GMT
Release Date Price: $29.82 (-1.58%)
Operator

Good day ladies and gentleman and welcome to Autolus Therapeutics Conference Call to discuss the initial results from the company's ALLCAR19 Phase 1/2 Trial in Adult Acute Lymphoblastic Leukemia presented at the AACR annual meeting yesterday.

(Operator Instructions)

As a reminder, this call is being recorded. I would now like to turn the call over to Ms. Silvia Taylor, VP Corporate Affairs and Communications.

Silvia Taylor
Autolus Therapeutics - VP Corporate Affairs and Communications

Thank you operator and good morning everyone. Thank you for joining our call today to review the initial clinical data from the ongoing Phase 1/2 ALLCAR19 Trial in patients with relapsed/refractory adult B-cell acute lymphoblastic leukemia or ALL presented at AACR yesterday as a late-breaking poster.

I am here with Dr. Claire Roddie, principal investigator of the ALLCAR19 trial from University College London in the United Kingdom. Also participating in this call are Dr. Christian Itin, Chairman and CEO; Dr. Martin Pule, Chief Scientific Officer and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot